- Home
- TOPS vs SONN Comparison
TOPS vs SONN Comparison
Compare TOPS & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- SONN
- Stock Information
- Founded
- TOPS 2000
- SONN N/A
- Country
- TOPS Greece
- SONN United States
- Employees
- TOPS N/A
- SONN N/A
- Industry
- TOPS Marine Transportation
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- SONN Health Care
- Exchange
- TOPS Nasdaq
- SONN Nasdaq
- Market Cap
- TOPS 27.2M
- SONN 24.2M
- IPO Year
- TOPS 2004
- SONN N/A
- Fundamental
- Price
- TOPS $5.46
- SONN $2.90
- Analyst Decision
- TOPS
- SONN Strong Buy
- Analyst Count
- TOPS 0
- SONN 1
- Target Price
- TOPS N/A
- SONN $20.00
- AVG Volume (30 Days)
- TOPS 8.3K
- SONN 557.9K
- Earning Date
- TOPS 11-13-2025
- SONN 08-13-2025
- Dividend Yield
- TOPS N/A
- SONN N/A
- EPS Growth
- TOPS N/A
- SONN N/A
- EPS
- TOPS 1.09
- SONN N/A
- Revenue
- TOPS $86,127,000.00
- SONN $1,000,000.00
- Revenue This Year
- TOPS $9.90
- SONN $5,376.22
- Revenue Next Year
- TOPS N/A
- SONN N/A
- P/E Ratio
- TOPS $4.99
- SONN N/A
- Revenue Growth
- TOPS 3.83
- SONN 1689.52
- 52 Week Low
- TOPS $5.00
- SONN $1.08
- 52 Week High
- TOPS $11.47
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- TOPS 40.92
- SONN 40.63
- Support Level
- TOPS $5.40
- SONN $3.02
- Resistance Level
- TOPS $5.70
- SONN $3.80
- Average True Range (ATR)
- TOPS 0.23
- SONN 0.31
- MACD
- TOPS -0.01
- SONN -0.03
- Stochastic Oscillator
- TOPS 13.00
- SONN 1.96
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.